AMINES & PLASTICIZERS LTD

All figures are consolidated, in INR M unless stated. FY ends 31 March. Primary source: StockAnalysis standardised statements (from exchange filings), cross-checked to AR FY2025 KPIs and FY2026 results. EBITDA FY2022–FY2025 is company-reported (AR FY2025). FY2026 EBITDA is derived as operating income plus D&A because company-reported full-year FY2026 EBITDA was not found.

Income statement

DPS is shown by the fiscal year to which the final dividend relates. FY2023–FY2026 final dividends of INR 0.50 (25% of face value) are confirmed by record dates of Sep 2023, Sep 2024, Sep 2025 and Sep 2026. The FY2026 EPS of INR 6.63 is from the company's results; standalone EPS differs slightly.

Margins

FY2021 reference point (AR FY2025): revenue INR 4,419 M, EBITDA margin 13.05%, PAT INR 325.9 M.

Revenue CAGR: FY2021–FY2025 (4-year): 10.6%. FY2022–FY2026 (4-year): 0.3%. FY2021–FY2026 (5-year): 5.3%. All derived.

Commentary. Three distinct phases are visible.

FY2022–FY2023: volume-led growth with margin compression. Revenue rose 26% in FY2022, but EBITDA margin fell from 13.05% (FY2021) to 8.06% and then 7.57%. EO and feedstock inflation outran pass-through.

FY2024–FY2025: margin restoration and the record year. EBITDA margin recovered to 11.1% and 10.6%. Absolute EBITDA reached INR 718 M and INR 703 M, and FY2025 PAT hit a record INR 410 M. The company attributes this to portfolio strength, domestic demand and 85% capacity utilisation at Unit 1 (AR FY2025).

FY2026: a revenue air-pocket with margin resilience. Revenue fell 13.6%. Management cited a curtailed EO supply during a supplier shutdown (Q2–Q3), weak export orders amid tariff and geopolitical uncertainty, and deferred customer replenishment. EBITDA margin held near 10.5% because the company shifted its mix toward an alternative higher-contribution product line (Q2 FY2026 commentary). Lower finance cost lifted net margin to a five-year high of 6.4%.

Quarterly trajectory (most recent five quarters)

Sources: Kotak Neo; Trendlyne (Q2 and Q4 FY2026 releases); Indian Chemical News (Q3 FY2026); SAHI (Q1 FY2027). Q1 FY2027 finance cost was INR 0.96 Cr versus INR 1.66 Cr a year earlier. Q4 FY2026 PAT of INR 15.35 Cr was the highest quarterly PAT in the dataset. It probably includes inventory and mix gains; management cited inventory gains again in Q1 FY2027.

Balance sheet

Notes:

• Long-term versus short-term debt split: the company reports borrowings as predominantly short-term working-capital lines from an SBI-led consortium plus unsecured member deposits (AR FY2025, MD&A). An exact split is n/d.

• FY2026: the cash-flow statement shows INR 502.3 M of short-term debt repaid and INR 2.4 M of long-term debt raised. This implies a sharp deleveraging, consistent with finance cost falling to INR 54.6 M in FY2026 and INR 9.6 M in Q1 FY2027. FY2026 closing debt is n/d. The company may now be near net-cash.

• FY2026 equity is derived as FY2025 equity + FY2026 PAT − dividend of about INR 27.5 M. Aggregator P/B ratios (3.07x at INR 175 on 23 Sep 2026; 3.4x at INR 184 on 28 Aug 2026) imply book value of about INR 2,980–3,140 M, so the derived figure is conservative.

Working capital (derived)

The cash conversion cycle lengthened to about 107 days in FY2026. The cause is receivables, which held at INR 1,392 M even as revenue fell 13.6%. This deserves monitoring as a possible sign of extended credit to export or domestic customers.

Cash flow

Commentary. Cash generation is highly sensitive to working capital. FY2022 operating cash flow was negative (−INR 266 M) because receivables and other assets swelled by about INR 600 M. FY2026 produced record operating cash flow (INR 664 M) as other operating assets released about INR 162 M. Capex intensity is extremely low: 0.2–1.5% of revenue, well below depreciation, and only INR 9.1 M in FY2026. This shows that APL is harvesting an existing asset base rather than reinvesting. Gross PP&E is ageing and net PP&E fell from INR 872 M to INR 758 M over five years. APL says it has "underutilised land" across about 43 acres for modular expansion (AR FY2025), but no expansion capex has been announced.

Returns and efficiency ratios

The return profile peaked in FY2024 at about 18% ROE and 17% ROCE and has since drifted lower. Two forces drive this: profit fell in FY2026, and an equity base growing about 13–17% a year is mostly retained cash that APL is not redeploying (payout ratio about 7%). Balance-sheet risk has fallen materially. Net debt/EBITDA dropped from 1.66x (FY2023) to 0.46x (FY2025), and interest coverage roughly doubled by FY2026.

Management guidance

APL gives no numerical guidance. The trajectory of its qualitative statements is:

FY2026 (Q2 commentary): expected to remain challenging, with further EO shutdown risk in Q4.

Q1 FY2027: stable operations, a healthy order book supporting sequential growth, margin protection via feedstock management and inventory gains, and fuel and gas constraints to monitor.

Structural: domestic business expected to remain robust; global collaborations to yield niche opportunities over longer gestation periods (AR FY2025).

Consensus

No sell-side consensus exists. On simple arithmetic, sustaining Q1 FY2027's run-rate (about INR 150 Cr revenue and INR 9.5 Cr PAT per quarter) implies FY2027 revenue of about INR 600–630 Cr and PAT of about INR 38–40 Cr. That would put FY2027 EPS at about INR 6.9–7.3, against a share price of INR 175. This is an analyst illustration, not guidance.

Bull case

1. The earnings trough is behind. Q4 FY2026 PAT rose 19.8% YoY to INR 15.35 Cr and Q1 FY2027 PAT rose 27% to INR 9.47 Cr, with revenue back to +7% growth and EBITDA margin expanding 75 bps to 10.06%. A return to FY2025 PAT (INR 41 Cr) would put the stock at about 23x trailing earnings with clear growth.

2. Balance-sheet transformation. INR 655 M of FY2026 FCF, about INR 502 M of debt repaid, and finance costs down about 42% YoY in Q1 FY2027 turn APL into a near-unlevered, cash-generative business. That cash could fund brownfield expansion on existing land without dilution.

3. Optionality in decarbonisation chemistry. An incumbent position in MDEA and formulated solvents, combined with developed CCUS and hydrogen formulations and MoUs with US and Japanese partners, offers a low-cost call option on carbon capture and hydrogen build-outs in India and the Middle East.

Bear case

1. Structurally inferior economics. Gross margin of about 26% and EBITDA margin of about 10.5% are roughly half those of Balaji and Alkyl. With no EO integration, APL stays a price-taker on its key input, and FY2022–FY2023 showed margins can collapse to about 7.5%.

2. Ex-growth, ex-investment. Revenue CAGR FY2022–FY2026 was 0.3%. Capex of about INR 9 M in FY2026 is far below depreciation and no expansion is announced, which risks capacity ceilings (85% utilisation) and asset obsolescence. At about 3x book and about 23x earnings, the stock already prices in recovery.

3. Concentration and governance risk. The business depends on one feedstock (EO shutdowns in FY2026), one region for a large share of exports (43.65% Middle East), a 73%-promoter shareholder base with zero institutional ownership, a combined Chair/MD, low payout, thin liquidity and minimal disclosure. These limit re-rating potential and raise minority-shareholder risk.

Catalysts and monitorables (next 12 months)

Analyst verdict

Amines & Plasticizers is a credible, cash-generative niche franchise trapped inside a structurally modest economic model. Its genuine assets are real. It holds pioneer status and a qualified customer base in Indian MDEA and formulated gas-treating solvents, claims dominance in domestic ethanolamines, has a globally relevant NMMO position, and has five decades of experience running hazardous EO/PO chemistry safely. These produce stable, if unspectacular, EBITDA margins of about 10–11%. They also proved resilient in FY2026: margins held near 10.5% while revenue fell 13.6% under an EO supply shock and export-demand deferral. The cash-flow outcome was the best in five years. APL generated INR 655 M of FCF, repaid roughly half its debt, and entered FY2027 with operating momentum, delivering Q4 FY2026 and Q1 FY2027 PAT growth of 20% and 27%.

The constraints are just as clear. APL is not backward-integrated, so its gross margins sit roughly 18–20 points below aliphatic-amine peers. Top-line growth over FY2022–FY2026 was essentially zero. Capex has been cut to almost nothing, and no expansion has been articulated despite land availability and 85% utilisation. Capital allocation is conservative to the point of passivity: a flat INR 0.50 dividend and a growing cash pile. Governance and disclosure are typical of a closely held Indian small-cap, with 73% promoter ownership, a combined Chair/MD, no institutional holders and no analyst consensus.

At about INR 175 (about 23x trailing P/E, about 3x book, about 14x EV/EBITDA), the market is paying a fair, not cheap, price for a cyclical recovery that is only two quarters old. The investment case hinges on two things. First, sustained margins of 10% or more as volumes recover. Second, management converting its CCUS, hydrogen and MoU optionality, and its strengthened balance sheet, into visible growth capex. Without that second step, APL remains a well-run but range-bound niche chemical producer. Stance: Neutral, with positive bias on improving earnings momentum. Key evidence to upgrade: a capex announcement or quantified partner-led revenue. Key evidence to downgrade: another EO-driven volume shock or a reversal of the Q1 FY2027 margin gains.

---

All figures are from public filings and data aggregators as cited. Items marked n/d were not found in the public sources reviewed and have not been estimated.